Return
Software supporting optimal experimental design: A case study of binary diffusion using EFCOSS
DOI:10.1016/j.compchemeng.2008.12.008.png)
Abstract
En 中文
Methods for optimal experimental design aim at minimizing uncertainty in parameter estimation problems. Despite their long tradition in applied mathematics and importance in practical applications, they are currently not widely used in computational science and engineering. To make the techniques of optimal experimental design more accessible to a broader community, we introduce a novel software environment called EFCOSS and demonstrate its ease of use and versatility in two case studies of binary diffusion experiments. Through the use of a component-based software architecture, integration of automatic differentiation technology and facilitated interfacing to optimization algorithms. EFCOSS minimizes the computational overhead for the user who can thus focus on model development and analysis itself. The presented case studies focus on diffusion experiments in liquids since these experiments are typically very demanding. The use of optimal experimental design techniques allows to reduce experimental time and effort significantly. (C) 2009 Elsevier Ltd. All rights reserved.
Keywords:
Optimal experimental design
Parameter estimation
EFCOSS
Diffusion experiment
Distributed computing
Automatic differentiation
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
C
IF:
3.9
Papers:
8.1K
Citations:
1.7W
Organization
Cited Papers
Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico
Hematology
IF0
Microsomal Cytochrome P450 Dependent Oxidation of N-Hydroxyguanidines, Amidoximes, and Ketoximes: Mechanism of the Oxidative Cleavage of Their CN(OH) Bond with Formation of Nitrogen Oxides
Biochemistry
IF0
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study
Lung Cancer
IF0

